Skip to main content

Table 5 Logistic regression model of the odds ratio of the EACS Guidelines Unlisted regimens in 333 HIV/HBV co-infected patients currently on anti-HBV treatment

From: Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy

Characteristics EACS GU regimens adjusted OR  
(95% CI) P
N. enrolled per center§   
≥20 patients 0.56 (0.23-1.37) 0.2
Female gender 1.92 (0.71-5.18) 0.2
Immigrant status   
Foreign birth 1.4 (0.71-2.74) 0.33
Age at diagnosis   
10 years increase 1.23 (1.02-1.48) 0.03
Years since diagnosis*   0.12
2-10 0.68 (0.24-1.9)
<10 1.08 (0.39-3.04)
Alcohol consumption   
Ever 2.21 (0.84-5.86) 0.11
Disease stage°   
Cirrhosis/HCC 1.57 (0.75-3.29) 0.23
HBeAg   
Positivity 0.83 (0.44-1.55) 0.56
HCV co-infection   
Yes 2.74 (1.39-5.41) 0.004
HDV co-infection   
Yes 0.41 (0.18-0.93) 0.03
Previous treatment   
Yes 0.4 (0.19-0.83) 0.01
  1. Reference: § = ≤20 patients enrolled; * = <2 years;° = chronic hepatitis. EACS, European AIDS Clinical Society; OR, odds ratio; CI, confidence interval; HCC, hepatocellular carcinoma.